WallStreetZenWallStreetZen

NASDAQ: RVNC
Revance Therapeutics Inc Stock Ownership - Who owns Revance Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Revance Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Erica JordanChief Commercial Officer2024-04-162,392$3.80
$9.10kSell
Dustin S. SjutsPresident2024-03-189,211$5.04
$46.45kSell
Dwight MoxieCLO GC2024-03-188,125$5.04
$40.97kSell
Tobin SchilkeCFO2024-03-189,361$5.04
$47.21kSell
Dustin S. SjutsPresident2024-03-152,967$5.31
$15.74kSell
Mark J. FoleyCEO2024-03-1517,228$5.31
$91.39kSell
Mark J. FoleyCEO2024-03-153,305$5.31
$17.53kSell
Tobin SchilkeCFO2024-03-153,822$5.31
$20.28kSell
Dwight MoxieCLO GC2024-03-153,269$5.31
$17.34kSell
Mark J. FoleyCEO2024-03-0630,000$6.98
$209.40kBuy

1 of 4

RVNC insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RVNC insiders and whales buy or sell their stock.

RVNC Shareholders

What type of owners hold Revance Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Capital World Investors13.53%11,939,076$45.49MInstitution
Ronald W. Eastman8.94%7,885,294$30.04MInsider
Blackrock Inc8.45%7,453,371$28.40MInstitution
Palo Alto Investors LP5.94%5,237,284$19.95MInstitution
Vanguard Group Inc5.75%5,069,625$19.32MInstitution
Franklin Resources Inc5.38%4,749,539$18.10MInstitution
Jpmorgan Chase Co5.26%4,643,419$17.69MInstitution
Essex Woodlands Health Ventures Fund Viii LP4.69%4,134,962$15.75MInsider
Polar Capital Holdings PLC3.59%3,169,239$12.07MInstitution
Jonathan Tunnicliffe3.51%3,096,650$11.80MInsider

1 of 3

RVNC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RVNC73.75%26.25%Net SellingNet Selling
AVXL31.49%5.04%Net BuyingNet Buying
ATAI7.99%37.92%Net SellingNet Selling
LXEO60.65%25.62%Net Buying
MGTX51.67%48.33%Net Buying
View Top Biotech Stocks

Revance Therapeutics Stock Ownership FAQ

Who owns Revance Therapeutics?

Revance Therapeutics (NASDAQ: RVNC) is owned by 82.08% institutional shareholders, 29.21% Revance Therapeutics insiders, and 0.00% retail investors. Ronald W. Eastman is the largest individual Revance Therapeutics shareholder, owning 7.89M shares representing 8.94% of the company. Ronald W. Eastman's Revance Therapeutics shares are currently valued at $29.65M.

If you're new to stock investing, here's how to buy Revance Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.